WO2026018064 - MULTISPECIFIC MULTI-DRUG ANTIBODY-DRUG CONJUGATES
National phase entry is expected:
Publication Number
WO/2026/018064
Publication Date
22.01.2026
International Application No.
PCT/IB2025/000358
International Filing Date
14.07.2025
Title **
[English]
MULTISPECIFIC MULTI-DRUG ANTIBODY-DRUG CONJUGATES
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT MULTI-MÉDICAMENT MULTISPÉCIFIQUES
Applicants **
MERUS N.V.
Inventors
DE KRUIF, Cornelis, Adriaan
MORTENSEN, Franziska
LOWE, Peter Richard
RUSSO, Giulio
SILVERMAN, Peter Brian
Priority Data
63/671,887
16.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4740 | |
| EPO | Filing, Examination, Granting | 62742 | |
| Japan | Filing, Examination, Granting | 4038 | |
| South Korea | Filing, Examination, Granting | 5907 | |
| USA | Filing, Examination, Granting | 20440 |
Total:
97,867
Contact Us
Abstract[English]
The present disclosure relates to the field of antibody-drug conjugates (ADCs). In particular it relates to the field of therapeutic antibodies for the treatment of disease, in particular for the treatment of cancer. More particularly it relates to multispecific multi-drug antibody-drug conjugates.[French]
La présente divulgation concerne le domaine des conjugués anticorps-médicament (ADC). En particulier, l'invention concerne le domaine des anticorps thérapeutiques pour le traitement d'une maladie, en particulier pour le traitement du cancer. Plus particulièrement, l'invention concerne des conjugués anticorps-médicament multi-médicament multispécifiques.